Please check your internet connection and try again.
# Diadzein + Genistein + Palmitoylethanolamide
## Overview
This combination contains isoflavones (daidzein, genistein) and palmitoylethanolamide (PEA). Isoflavones are phytoestrogens, and PEA is an endogenous fatty acid amide involved in pain and inflammation modulation. Evidence for this specific combination is limited.
## Primary Indications
Primarily used for management of pain and inflammation, particularly in conditions like vulvodynia and interstitial cystitis. May also be considered for menopausal symptom relief, though evidence is less robust for this combination.
## Adult Dosing
* **Vulvodynia/Pain:** Typically 1 capsule (containing Daidzein 120 mg, Genistein 120 mg, PEA 600 mg) twice daily. Some protocols may suggest higher doses based on symptom severity.
* **Menopausal Symptoms:** Dosing varies widely and is not well-established for this specific combination.
## Pediatric Dosing
No established pediatric dosing.
## Dose Adjustments
No specific dose adjustments for renal or hepatic impairment are established. Caution advised in patients with severe impairment.
## Contraindications
* Hypersensitivity to any component of the formulation.
* History of hormone-sensitive cancers (e.g., breast, uterine) or strong family history; use with caution due to phytoestrogen content.
## Adverse Effects
Generally well-tolerated. Potential adverse effects include:
* Gastrointestinal upset (nausea, bloating)
* Headache
* Allergic reactions
## Key Drug Interactions
* **Hormone Therapy:** Potential additive effects with hormone replacement therapy or other phytoestrogens.
* **Tamoxifen:** Isoflavones may interact with tamoxifen metabolism; avoid concurrent use without medical supervision.
* **Anticoagulants:** PEA lacks significant anticoagulant effects, but caution with concurrent anticoagulants is prudent due to limited data.
## Monitoring
* Symptom response (pain, inflammation, menopausal symptoms).
* Adverse effects.
* Consider discussion with a gynecologist or oncologist regarding risks in patients with a history of hormone-sensitive malignancies.
## Clinical Pearls
* This combination is often used off-label and evidence for its efficacy, particularly for menopausal symptoms, is less robust than for its individual components in specific indications.
* Consistent, long-term use may be required for optimal benefit, especially for pain management.
* Ensure patient understands the non-hormonal yet estrogen-like activity of isoflavones and potential risks in hormone-sensitive conditions.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and a qualified healthcare provider for specific patient care decisions.
